Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Go back to Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches| Oncolytics Biotech, Inc. (NASDAQ: ONCY) | Delayed: 0.96 +0.03 (3.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.93 | 52 Week High | $1.37 | |||
| Open | $0.95 | 52 Week Low | $0.24 | |||
| Day High | $0.98 | P/E | N/A | |||
| Day Low | $0.94 | EPS | $0.00 | |||
| Volume | 1,129,424 | |||||
